Safety of a mutagen-attenuated Rift valley fever virus vaccine in fetal and neonatal bovids

J. C. Morrill, C. A. Mebus, C. J. Peters

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Objective - To examine effects of in utero inoculation with a mutagen- attenuated Rift Valley fever virus (RVFV) vaccine (RVF MP-12) on fetal bovids and to assess the safety and efficacy of calfhood vaccination with RVF MP- 12. Animals - 18 pregnant Hereford and Hereford-type cows in the third or fifth month of gestation, their progeny, and 25 calves from cows immunized with RVF MP-12 during pregnancy. Procedure - Bovine fetuses were inoculated, via laparotomy, with 1 ml of RVF MP-12 containing 5 log10 plaque-forming units (PFU) of virus. Blood was obtained from newborn calves prior to their ingestion of colostrum. Immune-naive calves and calves born to RVF MP-12- vaccinated dams, ranging in age from 2 to 45 days, were vaccinated with RVF MP-12, and some were later challenge exposed with 1 ml of 5.7 log10 PFU of virulent RVFV strain ZH-501. Cows were monitored for viremia and antibody responses and for hematologic and serum biochemical alterations through parturition or abortion. Results - Surviving in utero-vaccinated calves were healthy, with no noticeable defects. Except for 1 vaccine-inoculated fetus that died on postinoculation day 21, all in utero-vaccinated fetuses had serum neutralizing antibody titer ≤ 1:20 st the time of delivery. All dams of in utero-vaccinated fetuses also developed neutralizing antibody titer. Calves born to cows vaccinated during gestation did not have antibody at birth, and all but 1 quickly acquired colostral antibody. Post-parturient inoculation of immune-naive calves and calves with colostral antibodies resulted in no untoward effects, and all calves with detectable neutralizing antibodies were protected against virulent virus challenge exposure. Conclusions - Fetal death and abortion would be rare even if fetuses were exposed to RVF MP-12. The trauma and complications associated with in utero inoculation do not make this a practical method of immunization. RVF MP-12 was safe, immunogenic, and protective in calves as young as 2 days of age.

Original languageEnglish (US)
Pages (from-to)1110-1114
Number of pages5
JournalAmerican Journal of Veterinary Research
Volume58
Issue number10
StatePublished - Oct 1997
Externally publishedYes

Fingerprint

Rift Valley fever virus
Mutagens
Fetus
Vaccines
calves
vaccines
Safety
Neutralizing Antibodies
fetus
Parturition
Pregnancy
Antibodies
neutralizing antibodies
vaccination
Viruses
cows
abortion (animals)
Colostrum
antibodies
Fetal Death

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Safety of a mutagen-attenuated Rift valley fever virus vaccine in fetal and neonatal bovids. / Morrill, J. C.; Mebus, C. A.; Peters, C. J.

In: American Journal of Veterinary Research, Vol. 58, No. 10, 10.1997, p. 1110-1114.

Research output: Contribution to journalArticle

Morrill, J. C. ; Mebus, C. A. ; Peters, C. J. / Safety of a mutagen-attenuated Rift valley fever virus vaccine in fetal and neonatal bovids. In: American Journal of Veterinary Research. 1997 ; Vol. 58, No. 10. pp. 1110-1114.
@article{c14198b169c646a18ef7ae2b157c5d57,
title = "Safety of a mutagen-attenuated Rift valley fever virus vaccine in fetal and neonatal bovids",
abstract = "Objective - To examine effects of in utero inoculation with a mutagen- attenuated Rift Valley fever virus (RVFV) vaccine (RVF MP-12) on fetal bovids and to assess the safety and efficacy of calfhood vaccination with RVF MP- 12. Animals - 18 pregnant Hereford and Hereford-type cows in the third or fifth month of gestation, their progeny, and 25 calves from cows immunized with RVF MP-12 during pregnancy. Procedure - Bovine fetuses were inoculated, via laparotomy, with 1 ml of RVF MP-12 containing 5 log10 plaque-forming units (PFU) of virus. Blood was obtained from newborn calves prior to their ingestion of colostrum. Immune-naive calves and calves born to RVF MP-12- vaccinated dams, ranging in age from 2 to 45 days, were vaccinated with RVF MP-12, and some were later challenge exposed with 1 ml of 5.7 log10 PFU of virulent RVFV strain ZH-501. Cows were monitored for viremia and antibody responses and for hematologic and serum biochemical alterations through parturition or abortion. Results - Surviving in utero-vaccinated calves were healthy, with no noticeable defects. Except for 1 vaccine-inoculated fetus that died on postinoculation day 21, all in utero-vaccinated fetuses had serum neutralizing antibody titer ≤ 1:20 st the time of delivery. All dams of in utero-vaccinated fetuses also developed neutralizing antibody titer. Calves born to cows vaccinated during gestation did not have antibody at birth, and all but 1 quickly acquired colostral antibody. Post-parturient inoculation of immune-naive calves and calves with colostral antibodies resulted in no untoward effects, and all calves with detectable neutralizing antibodies were protected against virulent virus challenge exposure. Conclusions - Fetal death and abortion would be rare even if fetuses were exposed to RVF MP-12. The trauma and complications associated with in utero inoculation do not make this a practical method of immunization. RVF MP-12 was safe, immunogenic, and protective in calves as young as 2 days of age.",
author = "Morrill, {J. C.} and Mebus, {C. A.} and Peters, {C. J.}",
year = "1997",
month = "10",
language = "English (US)",
volume = "58",
pages = "1110--1114",
journal = "American Journal of Veterinary Research",
issn = "0002-9645",
publisher = "American Veterinary Medical Association",
number = "10",

}

TY - JOUR

T1 - Safety of a mutagen-attenuated Rift valley fever virus vaccine in fetal and neonatal bovids

AU - Morrill, J. C.

AU - Mebus, C. A.

AU - Peters, C. J.

PY - 1997/10

Y1 - 1997/10

N2 - Objective - To examine effects of in utero inoculation with a mutagen- attenuated Rift Valley fever virus (RVFV) vaccine (RVF MP-12) on fetal bovids and to assess the safety and efficacy of calfhood vaccination with RVF MP- 12. Animals - 18 pregnant Hereford and Hereford-type cows in the third or fifth month of gestation, their progeny, and 25 calves from cows immunized with RVF MP-12 during pregnancy. Procedure - Bovine fetuses were inoculated, via laparotomy, with 1 ml of RVF MP-12 containing 5 log10 plaque-forming units (PFU) of virus. Blood was obtained from newborn calves prior to their ingestion of colostrum. Immune-naive calves and calves born to RVF MP-12- vaccinated dams, ranging in age from 2 to 45 days, were vaccinated with RVF MP-12, and some were later challenge exposed with 1 ml of 5.7 log10 PFU of virulent RVFV strain ZH-501. Cows were monitored for viremia and antibody responses and for hematologic and serum biochemical alterations through parturition or abortion. Results - Surviving in utero-vaccinated calves were healthy, with no noticeable defects. Except for 1 vaccine-inoculated fetus that died on postinoculation day 21, all in utero-vaccinated fetuses had serum neutralizing antibody titer ≤ 1:20 st the time of delivery. All dams of in utero-vaccinated fetuses also developed neutralizing antibody titer. Calves born to cows vaccinated during gestation did not have antibody at birth, and all but 1 quickly acquired colostral antibody. Post-parturient inoculation of immune-naive calves and calves with colostral antibodies resulted in no untoward effects, and all calves with detectable neutralizing antibodies were protected against virulent virus challenge exposure. Conclusions - Fetal death and abortion would be rare even if fetuses were exposed to RVF MP-12. The trauma and complications associated with in utero inoculation do not make this a practical method of immunization. RVF MP-12 was safe, immunogenic, and protective in calves as young as 2 days of age.

AB - Objective - To examine effects of in utero inoculation with a mutagen- attenuated Rift Valley fever virus (RVFV) vaccine (RVF MP-12) on fetal bovids and to assess the safety and efficacy of calfhood vaccination with RVF MP- 12. Animals - 18 pregnant Hereford and Hereford-type cows in the third or fifth month of gestation, their progeny, and 25 calves from cows immunized with RVF MP-12 during pregnancy. Procedure - Bovine fetuses were inoculated, via laparotomy, with 1 ml of RVF MP-12 containing 5 log10 plaque-forming units (PFU) of virus. Blood was obtained from newborn calves prior to their ingestion of colostrum. Immune-naive calves and calves born to RVF MP-12- vaccinated dams, ranging in age from 2 to 45 days, were vaccinated with RVF MP-12, and some were later challenge exposed with 1 ml of 5.7 log10 PFU of virulent RVFV strain ZH-501. Cows were monitored for viremia and antibody responses and for hematologic and serum biochemical alterations through parturition or abortion. Results - Surviving in utero-vaccinated calves were healthy, with no noticeable defects. Except for 1 vaccine-inoculated fetus that died on postinoculation day 21, all in utero-vaccinated fetuses had serum neutralizing antibody titer ≤ 1:20 st the time of delivery. All dams of in utero-vaccinated fetuses also developed neutralizing antibody titer. Calves born to cows vaccinated during gestation did not have antibody at birth, and all but 1 quickly acquired colostral antibody. Post-parturient inoculation of immune-naive calves and calves with colostral antibodies resulted in no untoward effects, and all calves with detectable neutralizing antibodies were protected against virulent virus challenge exposure. Conclusions - Fetal death and abortion would be rare even if fetuses were exposed to RVF MP-12. The trauma and complications associated with in utero inoculation do not make this a practical method of immunization. RVF MP-12 was safe, immunogenic, and protective in calves as young as 2 days of age.

UR - http://www.scopus.com/inward/record.url?scp=0030874806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030874806&partnerID=8YFLogxK

M3 - Article

C2 - 9328663

AN - SCOPUS:0030874806

VL - 58

SP - 1110

EP - 1114

JO - American Journal of Veterinary Research

JF - American Journal of Veterinary Research

SN - 0002-9645

IS - 10

ER -